Vivimed Labs successfully completes USFDA inspection of its manufacturing facility

Vivimed Labs has recently successfully completed inspection of its API manufacturing facility in Spain.

After the completion of inspection Vivimed said “the USFDA inspectors concluded that the facility, its systems and practices comply with USFDA requirements with no observations reported on Form 483,".

Vivimed Labs MD and CEO Santosh Varalwar said "This is in line with the group's constant focus on maintaining high levels of regulatory compliance, which is a key differentiator in today's regulatory landscape, in the global generics pharmaceutical market."

The audit was conducted during the second week of September, which concluded on September18, 2015, he added.